{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 55,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "Details specific patient enrollment numbers (~80 total, ~60 for primary analysis) and dosing randomization criteria.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/28",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.92,
        "x": 0.028,
        "y": 0.24
      },
      "kind": "list",
      "text": "UPS Phase 2, part 2 potentially registrational study\nEnrolling total of ~80 AXL-expressing UPS patients in Phase 2, part 2\nFDA supportive of investigating a more frequent dosing regimen (3Q4W 44% and 2Q3W 38% increased exposure over Q2W)\nFirst 40 patients with a TmPS >=50% will be randomized 1:1 to 3Q4W or 2Q3W dosing regimen\nAdditional 40 patients to be enrolled at the selected dose\nPrimary efficacy endpoint is objective response rate (ORR) per RECIST v1.1\nPrimary efficacy analysis will be based on ~60 patients treated at the selected dosing regimen\nPrior systemic regimens limited to <=3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5b200ab-f999-4a18-8976-8a278e757542",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.033,
        "y": 0.083
      },
      "kind": "title",
      "text": "CAB-AXL (BA3011) Phase 2 Potentially Registrational UPS Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35d99b60-27c3-42c9-8657-30ad1776f471",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "46aaaeb3-111b-4ed9-9dc9-0b808ec45814",
      "evidence": "This slide contains a list/bullet component with multiple points.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 24,
      "beatId": "9bcd5a0a-740c-4853-97bc-75472d60fcdf",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "Market sizing and potential opportunities are discussed on pages 24-29.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}